Is fat anterior to the psoas muscle below the lower pole of the left kidney a common site for lymph node metastasis from T1a renal cell carcinoma (kidney cancer)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Fat anterior to the psoas muscle below the lower pole of the left kidney is not a common site for lymph node metastasis from T1a kidney cancer. T1a kidney cancers are small tumors (less than 4 cm) confined to the kidney, and they generally have a low risk of metastasis, with less than 5% spreading to lymph nodes 1. When kidney cancer does metastasize to lymph nodes, it typically follows predictable drainage patterns, primarily involving the hilar, para-aortic, and paracaval lymph nodes rather than fat deposits anterior to the psoas muscle. The location described is anatomically distinct from the typical lymphatic drainage pathway of the kidney. Additionally, T1a renal cell carcinomas have an excellent prognosis with five-year survival rates exceeding 90%, largely because they rarely metastasize 1. If an abnormality is noted in the fat anterior to the psoas muscle, other explanations such as normal anatomical fat variation, inflammatory changes, or a primary process unrelated to the kidney cancer would be more likely explanations than metastatic disease from a T1a renal tumor. The European Association of Urology guidelines also support the notion that lymph node dissection is not routinely recommended for patients with organ-confined disease, further suggesting that metastasis to lymph nodes in atypical locations is uncommon 1. Given the low risk of metastasis and the excellent prognosis associated with T1a kidney cancers, it is reasonable to prioritize other explanations for abnormalities in the fat anterior to the psoas muscle over metastatic disease from a T1a renal tumor.

From the Research

Lymph Node Metastasis in T1a Renal Cell Carcinoma

  • The provided studies do not specifically address the location of fat anterior to the psoas muscle below the lower pole of the left kidney as a common site for lymph node metastasis from T1a renal cell carcinoma.
  • However, studies have investigated the patterns of metastasis in renal cell carcinoma, including lymph node involvement 2, 3, 4, 5.
  • Lymph node metastasis is a common feature of disease progression in most solid organ malignancies, including renal cell carcinoma 6.
  • The most common sites of metastasis in T1a renal cell carcinoma are bone, lung, liver, and brain, with bone being the most common site 2.
  • Lymphadenectomy (lymph node dissection) is a staging procedure for detecting lymph node invasion, but its therapeutic benefit in renal cell carcinoma is still controversial 3.
  • Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases, but rather inflammatory changes or follicular hyperplasia 4.
  • Tumor size and history of diabetes mellitus are independently associated with metastasis in T1a renal cell carcinoma 5.

Patterns of Metastasis

  • The patterns of metastasis in renal cell carcinoma can vary, with some studies suggesting that lymph node metastasis may not always be a precursor to distant metastasis 6, 2.
  • The extent of lymph node dissection remains a matter of controversy, with some studies suggesting that an extended lymph node dissection may be beneficial in patients with locally advanced disease or unfavorable clinical and pathologic characteristics 3.
  • The risk of metastasis in T1a renal cell carcinoma is low but nonnegligible, and patients with small renal masses should be counseled on this risk when offered active surveillance 5.

Related Questions

Is fat anterior to the psoas muscle below the lower pole of the left kidney a common site for lymph node metastasis from T1a renal cell carcinoma (kidney cancer)?
Does the fat anterior to the psoas muscle, located below the lower pole of the left kidney, lack lymph nodes and is it not a site for metastatic lymph nodes from renal (kidney) cancer?
Is fat anterior to the psoas muscle below the lower pole of the left kidney a common site for lymph node metastasis in T1a kidney cancer?
Does the fat anterior to the psoas muscle (psoas major) below the lower pole of the left kidney contain lymph nodes that are part of the lymphatic chain for the kidneys and a potential location for metastatic lymph nodes from renal cell carcinoma (kidney cancer)?
Is it common for a metastatic lymph node from a low-grade Renal Cell Carcinoma (RCC) to occur in the fat anterior to the psoas muscle below the lower pole of the left kidney?
Is a 3mm lesion in the fat anterior to the psoas muscle, caudal to the lower pole of the left kidney, consistent with lymph node metastasis from a T1a kidney cancer, given its stable size and maturation over 3 years post-surgery?
Is a 3mm lesion in the fat anterior to the psoas muscle, caudal to the lower pole of the left kidney, consistent with lymph node metastasis from a T1a kidney cancer, given its stable size and maturation over 3 years post-surgery?
What is the role of Lov-DHEA (Dehydroepiandrosterone)?
Is fat anterior to the psoas muscle below the lower pole of the left kidney a common site for lymph node metastasis from T1a renal cell carcinoma (kidney cancer)?
Is fat anterior to the psoas muscle below the lower pole of the left kidney a common site for lymph node metastasis from T1a renal cell carcinoma (kidney cancer)?
What causes an increase in Dehydroepiandrosterone (DHEA)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.